Merck hires Variational AI to design small-molecule drug candidates in a deal worth up to $349 million
Variational AI will fine-tune its Enki platform on Merck's proprietary data for two undisclosed targets; the upfront payment is not disclosed.
Why it matters
The deal is another sign that big pharma is paying for generative chemistry built on its own data rather than on public datasets alone. Merck gets exclusive rights to develop and sell any compounds, while Variational AI, a Vancouver company founded by researchers from MIT, Caltech, Google Research, Microsoft Research and D-Wave, earns milestones if candidates advance. The value is a ceiling, not cash today, so the test is whether fine-tuned models deliver candidates that reach the clinic; watch for named targets or a first milestone.
Key facts
- Deal value up to US$349 million
- Two undisclosed targets designated by Merck
- Enki platform fine-tuned on Merck proprietary data
- Merck holds exclusive development and commercial rights
- Variational AI is based in Vancouver